SC: Statutory Authorities may Intervene When Housing Societies Delay Membership Decisions || SC: Quasi-Judicial Authorities Cannot Exercise Review Powers Unless Expressly Granted By Statute || SC: Special Court Cannot Order Confiscation While Appeal Against Attachment Confirmation is Pending || SC: Photocopies are Not Evidence Unless Conditions for Leading Secondary Evidence are Proved || Calcutta HC: Conviction under Essential Commodities Act Invalid if Stock Measured With a 'Stick' || Kerala High Court: Universities Must Regulate Student Political Activities to Curb Campus Violence || Calcutta HC: Accused Has No Right on Investigation Mode or Impleadment in Probe Writ || Gauhati HC: POCSO Probes Must be Child-Friendly, With Sensitized Investigators to Ensure Clear Truth || Kerala HC: Orders Barring Disclosure of Witness Statements Must State Reasons For Each Witness || SC: Hard to Believe Married Woman Was Lured Into Sex by False Marriage Promise; Case Quashed

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :